What is the latest price situation of grefituzumab in 2025?

Glofitamab (Glofitamab), as an innovative dual-antibody drug developed by Roche, has rapidly expanded its use around the world since it was approved in Europe and the United States in 2023. In 2024, the drug was officially approved for marketing in mainland China, with the trade name Columvi injection. It is mainly used to treat patients with relapsed or refractory DLBCL (non-Hodgkin lymphoma), especially those who have received at least two systemic treatments. The entry of this drug marks a key step in the field of dual-antibody immunotherapy in China.

Currently, gratinumab has not been included in the national medical insurance directory, so its market price is relatively high. According to the price data published in the domestic market version, each box of 10mg/10ml injection is priced at about 30,000 yuan.

In contrast, in the European market, the original research versionColumvi is priced higher. In some countries such as Germany and France, the price of a single box even exceeds RMB 40,000, which is mainly affected by local tax and medical insurance policies. Currently, no generic or biosimilar drugs have been approved for marketing, so global supply remains the exclusive responsibility of the originator companies. In addition, because this drug is a highly specialized preparation, it can usually only be administered in specialized hospitals such as tertiary cancer centers, hematology departments, or immunology departments, and requires immunological and imaging follow-up.

Judging from market trends, despite its high price, gratinumab is still regarded by many patients and doctors as a powerful alternative to CAR-T therapy due to its innovative mechanism of action, rapid onset of action, and convenience without the need for cell transfusion. In the future, if it enters into medical insurance or carries out volume purchasing, its accessibility and affordability are expected to be significantly improved. At the same time, it is recommended that patients obtain drugs through official channels and develop the most appropriate treatment path under the guidance of a doctor based on their own condition.

Reference materials:https://www.drugs.com/glofitamab.html